Delta Resources Ltd. (DTARF)

Overview

Cleo Diagnostics Ltd is a pioneering medical diagnostics and devices company established in 2021 and headquartered in Melbourne, Australia. The core mission of Cleo Diagnostics is centered around the development and commercialization of non-invasive blood tests for the early detection of ovarian cancer. By focusing on innovative and accessible diagnostic solutions, the company aims to significantly improve early detection rates and outcomes for individuals at risk of ovarian cancer in Australia. Cleo Diagnostics is also dedicated to the advancement of its research and development efforts, working on securing intellectual property and patents to underpin its diagnostic technologies.

Products and Services

• CleoDX Pre-Surgical Triage Tests

This cutting-edge diagnostic tool offered by Cleo Diagnostics represents a significant advancement in the management of ovarian cancer. The CleoDX test utilizes a proprietary combination of serum biomarkers to accurately assess the malignancy risk associated with ovarian tumors. Designed to be administered prior to surgical referral, this non-invasive blood test aims to improve the decision-making process for medical professionals, ensuring that patients receive the most appropriate level of care based on their individual risk assessment.